PROLIGHT DIAGNOSTICS AB |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.155 SEK | -4.91% |
|
+1.31% | -48.50% |
| Sales 2021 | 108K 9.9K 13.55K | Sales 2022 | 35.27M 3.25M 4.44M | Capitalization | 54.76M 5.04M 6.9M |
|---|---|---|---|---|---|
| Net income 2021 | -6M -553K -756K | Net income 2022 | -12M -1.11M -1.51M | EV / Sales 2021 | 1,006 x |
| Net cash position 2021 | 43.89M 4.04M 5.53M | Net cash position 2022 | 54.11M 4.98M 6.82M | EV / Sales 2022 | 0.02 x |
| P/E ratio 2021 |
-22.2
x | P/E ratio 2022 |
-
| Employees | 6,069 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 42.56% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -4.91% | ||
| 1 week | +1.31% | ||
| Current month | -17.11% | ||
| 1 month | -17.11% | ||
| 3 months | -29.22% | ||
| 6 months | -47.10% | ||
| Current year | -48.50% |
1 week
0.12
0.18
1 month
0.120.18
Current year
0.120.29
1 year
0.121.70
3 years
0.121.83
5 years
0.124.30
10 years
0.128.06
| Managers | Title | Age | Since |
|---|---|---|---|
Masoud Khayyami
FOU | Founder | 61 | 98-12-31 |
Ulf Bladin
CEO | Chief Executive Officer | 60 | 20-06-30 |
Henrik Ljung
DFI | Director of Finance/CFO | 66 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | 05-12-31 | |
Maria Holmlund
BRD | Director/Board Member | 68 | - |
Masoud Khayyami
FOU | Founder | 61 | 98-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-02 | 0.141 | -9.03% | 2,165,157 |
| 24-04-30 | 0.155 | -4.91% | 1,088,339 |
| 24-04-29 | 0.163 | -8.94% | 5,495,248 |
| 24-04-26 | 0.179 | +45.53% | 26,002,853 |
| 24-04-25 | 0.123 | -3.91% | 7,823,908 |
End-of-day quote NORDIC GROWTH MARKET, April 29, 2024
More quotes
Prolight Diagnostics AB (publ) is a Sweden-based medical technology company. Together with Technology Partners, the Company develops patient-close test systems based on patented technology, for use in so-called Point of Care Testing (POCT). POCT tests are performed outside the traditional hospital laboratory, small mobile instruments enable testing near the patient and provide quick test answers. The Company focuses on the heart marker troponin.
Calendar
2024-05-16
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -48.50% | 7.06M | |
| -18.16% | 11.03B | |
| +58.43% | 3.5B | |
| -31.31% | 2.23B | |
| -14.31% | 2.16B | |
| -26.61% | 1.54B | |
| +34.35% | 1.12B | |
| -3.28% | 737M | |
| -22.75% | 477M | |
| -40.20% | 411M |
- Stock Market
- Equities
- PRLD Stock
